Previous close | 1.0500 |
Open | 0.8000 |
Bid | 0.6500 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 0.8000 - 1.0500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Fate Therapeutics ( NASDAQ:FATE ) First Quarter 2024 Results Key Financial Results Net loss: US$48.0m (loss widened by...
Despite Revenue Growth, Losses Widen; Clinical Trials Progress in Autoimmune and Cancer Treatments
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?